Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Experts call for “Disability Inclusive Health Care System” to address health inequity

We must try to make the health care system more accessible for people with disabilities

EU and European Disability Forum laud efforts of Sightsavers in India

This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities

National Policy Dialogue adopts landmark 10-point declaration for people with disabilities

World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection

SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device

Bayer pushes stroke prevention drug forward in China as regulators accept key filing

Stroke is the second-leading cause of death and the third-leading cause of disability worldwide

Tata AIA launches ‘Shubh Health Criti’ blending life cover with wellness and investments

New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security

India Autism Center hosts ‘Sports for All’ initiative to advance inclusive sporting ecosystem

Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents